This retrospective study involving 7 institutions evaluated the utility of PET for mediastinal staging in patients who had undergone resection of pulmlonary carcinoid tumors and nodal dissection. 88% of pts had typical carcinoid tumors. The sensitivity of PET was only 33%, whereas the specificity was 94%.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
August 15, 2014
August 14, 2014
Laurie Fenton Ambrose, President and CEO of the Lung Cancer Alliance, discusses lung cancer screening from the patient’s perspective.
August 11, 2014
Data from 6 cohort studies were evaluated to assess the ongoing risk of mesothelioma more than 40 years after initial environmental exposure to asbestos. Among over 22,000 of those exposed, 707 cases of pleural mesothelioma were diagnosed. The rate and risk increased until 45 years after exposure, then the rate of increase tapered off somewhat.
Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non–Small-Cell Lung Cancer
August 9, 2014
This multiinstitutional randomized trial compared sublobar resection alone to sublobar resection with adjuvant brachytherapy in high risk patients with peripheral NSCLC <3cm. Time to and type of local recurrence were similar between the groups. Brachytherapy did not importantly improve local control in patients with potentially compromised margi
Recurrence and Survival Outcomes After Anatomic Segmentectomy Versus Lobectomy for Clinical Stage I Non–Small-Cell Lung Cancer: A Propensity-Matched Analysis
August 9, 2014
This single-institution retrospective study used propensity score matching to compare long-term outcomes of anatomic segmentectomy vs lobectomy for early stage non-small cell lung cancer. A total of 312 pts were matched in each group. Locoregional and overall recurrence rates were similar between the groups. Freedom from recurrence (70% for segme
Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901
August 9, 2014
This randomized trial involving 30 centers in France compared outcomes after induction chemoradiotherapy followed by resection to resection alone for stage I or II esophageal cancer. The R0 resection rate was similar between the groups. Postoperative mortality was higher in the induction therapy group (11.1% vs 3.4%). Long-term survival was simila
Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220
August 5, 2014
Optimal management of superior sulcus tumors remains challenging. This SWOG protocol was a feasibility study of the utility of consolidation therapy with docetaxel in addition to cisplatin-etoposide, 45Gy, and possible resection. Of 46 registered pts, 86% completed induction therapy, 66% underwent resection, and 45% completed consolidation therapy
Survival of Australian lung cancer patients and the impact of distance from and attendance at a thoracic specialist centre: a data linkage study
July 29, 2014
Records of nearly 24,000 Australian patients with NSCLC were evaluated to determine the relationship between distance to the nearest speciality hospital (NASH) and survival. Increasing distance from a NASH was associated with decreasing likelihood of admission to a NASH and decreasing likelihood of lung cancer resection, resulting in an increasing h
Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction
July 29, 2014
Using data from 2 centers in London, outcomes after induction therapy and resection for esophageal cancer were analyzed according to the pathological response to induction therapy. Downstaging was the strongest predictor of survival (HR 0.43). Downstaging was also associated with a lower rate of local recurrence (6% vs 13%) and systemic recurrence
July 28, 2014
The authors queried whether PET has utility in clinically staging Tis or T1 esophageal cancers; this was a single institution retrospective study involving 79 pts. The incidence of FDG uptake increased with increasing T status, as did the SUV. Nodal staging was false positive in 3 pts and false negative all 13 pts with nodal involvement. Metastati